Trimtech Therapeutics
0 followers
About Trimtech Therapeutics
Trimtech Therapeutics Limited focuses on developing differentiated degraders to treat CNS and inflammatory disorders by selectively removing disease-associated toxic protein aggregates. The company’s TRIMTACs and TRIMGLUEs leverage the ubiquitin ligase TRIM21 to target and degrade pathogenic proteins, aiming to address intractable neurodegenerative and inflammatory conditions from its headquarters in the United Kingdom.